PharmaCyte Biotech Inc (PMCB)

[Deborah1]

Nuvilex Read for yourself, then decide...

http://www.nuvilex.com/latest-news/118-nuvilex-scheduled-to-begin-preclinical-studies-in-early-august


“Translational Drug Development, LLC (TD2) will conduct the study.”
“Nuvilex's pancreatic cancer treatment, which combines the Cell-in-a-Box(R) live-cell encapsulation technology with the well-known anticancer drug ifosfamide, will be studied with the expectation that it can improve the quality of life of pancreatic cancer patients by slowing down the accumulation of ascites fluid in the abdomen.”
“The live cells are expected to arrive at TD2's facility in Scottsdale, Arizona, during the first week of August 2014. The preclinical study will commence almost immediately after their arrival.”


http://td2inc.com/

Nuvilex Retains TD2 to Conduct Preclinical and Clinical Studies...READ MORE >
"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."
In commenting on TD2's work with Nuvilex, Kenneth L. Waggoner, Chief Executive Officer and President of Nuvilex, stated, "We are honored that TD2 and Dr. Von Hoff will play a pivotal role in the development of our treatment for patients with advanced pancreatic cancer that combines the proprietary Cell-in-a-Box live-cell encapsulation technology with the cancer drug ifosfamide. TD2 integrates world-class preclinical, clinical and regulatory expertise and provides unique drug development services aimed at minimizing the risk for its clients in the oncology drug development industry. In addition, access to the PCRT that is enabled by our association with TD2 will not only make Nuvilex's approach widely known, but should facilitate its development as we move forward. The sincere interest in our advanced pancreatic cancer treatment that has been shown by TD2 is particularly rewarding to all of us."

Long & Strong on my investment in this company!